Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, A-Alpha Bio is raising $2,844,988.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, David Younger played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About A-Alpha Bio

At A-Alpha Bio, we aim to accelerate target discovery, library screening, and preclinical drug characterization by providing cell-based tools for quantitative and high-throughput measurements of protein interactions. Current approaches for measuring protein interactions are insufficient for many drug development applications due to low accuracy or throughput.

To learn more about A-Alpha Bio, visit http://www.aalphabio.com/

Contact:
David Younger, Chief Executive Officer
206-890-9704
https://www.linkedin.com/in/david-a-younger/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved